Asset Details
Do you wish to reserve the book?
Azole Resistance and CYP51A/B Mutations in Aspergillus Clinical Isolates Before and During the COVID-19 Pandemic: A Molecular Surveillance Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Azole Resistance and CYP51A/B Mutations in Aspergillus Clinical Isolates Before and During the COVID-19 Pandemic: A Molecular Surveillance Study
Do you wish to request the book?
Azole Resistance and CYP51A/B Mutations in Aspergillus Clinical Isolates Before and During the COVID-19 Pandemic: A Molecular Surveillance Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Azole Resistance and CYP51A/B Mutations in Aspergillus Clinical Isolates Before and During the COVID-19 Pandemic: A Molecular Surveillance Study
2026
Overview
We conducted a cross-sectional study to (I) determine the relative frequency of antifungal-resistant Aspergillus clinical isolates, (II) address changes in susceptibility to available antifungals in patients infected with Aspergillus spp. with COVID-19, and (III) determine mutations in the CYP51A and CYP51B genes of Aspergillus spp. Isolated from the clinical specimens. A total of 30 fungal species were enrolled in the study. The antifungal activities of itraconazole and voriconazole were assessed using azole-containing agar media in Petri dishes. After identifying resistance in the isolates, the CYP51A and CYP51B gene regions were sequenced using the designed primers, and mutations were identified. To amplify CYP51A and CYP51B, primers with the specified sequences were used. Genomic DNA from 22 azole-resistant Aspergillus isolates was amplified using the CYP51-A and CYP51-B gene primers. 12/22 (54.54%) azole-resistant A. flavus isolates with the Tandem Repeat (TR34)/L98H (leucine-to-histidine substitution) mutation, MICs above the CLSI Epidemiological Cutoff Value. One carried the F46Y /TR34. 5/22 azole non-WT A. fumigatus isolates, CYP51-A analysis revealed that M220I, S297T/ TR34/L98H mutations, 4 A.orezea isolates had C498T/TR34 at a CYP51-B gene. Antifungal susceptibility testing should be performed when possible, and efficient systems must be implemented to monitor the evolution of newly introduced azole-resistant Aspergillus spp. In addition, these data are useful for clinicians to understand the incidence of azole resistance, enabling optimal management of affected patients and helping choose the right solution for infection management.
Publisher
Tehran University of Medical Sciences
